Cargando…
In vivo analysis of insulin-like growth factor type 1 receptor humanized monoclonal antibody MK-0646 and small molecule kinase inhibitor OSI-906 in colorectal cancer
The development and characterization of effective anticancer drugs against colorectal cancer (CRC) is of urgent need since it is the second most common cause of cancer death. The study was designed to evaluate the effects of two IGF-1R antagonists, MK-0646, a recombinant fully humanized monoclonal a...
Autores principales: | LEIPHRAKPAM, PREMILA D., AGARWAL, EKTA, MATHIESEN, MICHELLE, HAFERBIER, KATIE L., BRATTAIN, MICHAEL G., CHOWDHURY, SANJIB |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
D.A. Spandidos
2014
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3868504/ https://www.ncbi.nlm.nih.gov/pubmed/24173770 http://dx.doi.org/10.3892/or.2013.2819 |
Ejemplares similares
-
Akt inhibitor MK-2206 promotes anti-tumor activity and cell death by modulation of AIF and Ezrin in colorectal cancer
por: Agarwal, Ekta, et al.
Publicado: (2014) -
Differential PKA activation and AKAP association determines cell fate in cancer cells
por: Hedrick, Erik D, et al.
Publicado: (2013) -
Establishment and Validation of an Orthotopic Metastatic Mouse Model of Colorectal Cancer
por: Rajput, Ashwani, et al.
Publicado: (2013) -
Ridaforolimus (MK-8669) synergizes with Dalotuzumab (MK-0646) in hormone-sensitive breast cancer
por: Becker, Marc A., et al.
Publicado: (2016) -
Randomized, phase I/II study of gemcitabine plus IGF-1R antagonist (MK-0646) versus gemcitabine plus erlotinib with and without MK-0646 for advanced pancreatic adenocarcinoma
por: Abdel-Wahab, Reham, et al.
Publicado: (2018)